Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

CPRX – Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals, Inc.
CPRX
$22.52
Name : Catalyst Pharmaceuticals, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $2,746,516,736.00
EPSttm : 1.31
finviz dynamic chart for CPRX
Catalyst Pharmaceuticals, Inc.
$22.52
1.49%
$0.33

Float Short %

7.13

Margin Of Safety %

42

Put/Call OI Ratio

0.27

EPS Next Q Diff

0.06

EPS Last/This Y

0.56

EPS This/Next Y

0.24

Price

22.52

Target Price

33.88

Analyst Recom

1.12

Performance Q

-0.62

Relative Volume

0.54

Beta

0.73

Ticker: CPRX




22 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-03-20CPRX23.10.200.024573
2025-03-21CPRX24.220.210.234392
2025-03-24CPRX25.730.130.092138
2025-03-25CPRX25.720.140.112881
2025-03-26CPRX25.130.140.083126
2025-03-27CPRX24.840.130.673174
2025-03-28CPRX24.680.140.323294
2025-03-31CPRX24.260.140.263252
2025-04-01CPRX23.850.150.073288
2025-04-02CPRX24.460.150.113317
2025-04-03CPRX24.120.150.033516
2025-04-04CPRX23.050.141.963637
2025-04-07CPRX21.850.200.123891
2025-04-08CPRX21.410.210.903824
2025-04-09CPRX22.740.211.013831
2025-04-10CPRX21.530.243.313931
2025-04-11CPRX22.040.300.294170
2025-04-14CPRX22.80.300.044178
2025-04-15CPRX23.210.290.104222
2025-04-16CPRX22.20.290.204268
2025-04-17CPRX22.550.270.074236
2025-04-18CPRX22.520.270.084236
DateSymbolLastP/C OIP/C VolTotal OI
22 items Current Page1 of 1




22 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-03-20CPRX23.1643.453.92.18
2025-03-21CPRX24.2243.460.02.18
2025-03-24CPRX25.7443.464.82.18
2025-03-25CPRX25.7243.446.32.18
2025-03-26CPRX25.1543.440.12.18
2025-03-27CPRX24.8439.543.02.16
2025-03-28CPRX24.6939.544.72.16
2025-03-31CPRX24.2639.541.42.16
2025-04-01CPRX23.9239.542.52.16
2025-04-02CPRX24.4639.553.22.16
2025-04-03CPRX24.1239.542.52.16
2025-04-04CPRX23.0539.533.72.16
2025-04-07CPRX21.8439.530.72.16
2025-04-08CPRX21.4039.540.92.16
2025-04-09CPRX22.7439.565.32.16
2025-04-10CPRX21.4639.529.82.16
2025-04-11CPRX22.0539.554.72.16
2025-04-14CPRX22.8039.556.72.16
2025-04-15CPRX23.2339.552.12.16
2025-04-16CPRX22.1839.533.32.16
2025-04-17CPRX22.5239.551.02.16
2025-04-18CPRX22.5239.546.51.94
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
22 items Current Page1 of 1




22 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-03-20CPRX-10.372.505.63
2025-03-21CPRX-10.372.505.63
2025-03-24CPRX-10.372.295.63
2025-03-25CPRX-10.372.295.63
2025-03-26CPRX-10.372.296.54
2025-03-27CPRX-10.372.296.54
2025-03-28CPRX-10.372.296.54
2025-03-31CPRX-10.372.296.54
2025-04-01CPRX-10.372.296.54
2025-04-02CPRX-10.372.296.54
2025-04-03CPRX-10.372.296.54
2025-04-04CPRX-10.372.296.54
2025-04-07CPRX-10.372.306.54
2025-04-08CPRX-10.372.306.54
2025-04-09CPRX-10.372.306.54
2025-04-10CPRX-10.372.307.16
2025-04-11CPRX-10.372.307.16
2025-04-14CPRX-10.372.517.16
2025-04-15CPRX-10.372.517.16
2025-04-16CPRX-10.332.517.13
2025-04-17CPRX-10.332.517.13
2025-04-18CPRX-10.332.517.13
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
22 items Current Page1 of 1

Last Quarter Act. EPS

0.44

Avg. EPS Est. Current Quarter

0.53

Avg. EPS Est. Next Quarter

0.5

Insider Transactions

-10.33

Institutional Transactions

2.51

Beta

0.73

Average Sales Estimate Current Quarter

130

Average Sales Estimate Next Quarter

140

Fair Value

32.02

Quality Score

93

Growth Score

100

Sentiment Score

75

Actual DrawDown %

13.9

Max Drawdown 5-Year %

-45.4

Target Price

33.88

P/E

17.21

Forward P/E

13.43

PEG

1.38

P/S

5.59

P/B

3.74

P/Free Cash Flow

11.48

EPS

1.31

Average EPS Est. Cur. Y​

1.94

EPS Next Y. (Est.)

2.19

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

33.33

Relative Volume

0.54

Return on Equity vs Sector %

2.5

Return on Equity vs Industry %

15.9

EPS 1 7Days Diff

-0.2

EPS 1 30Days Diff

-0.23

EBIT Estimation

46.5
Catalyst Pharmaceuticals, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 181
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizures; Ruzurgi for the treatment of pediatric LEMS patients; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
stock quote shares CPRX – Catalyst Pharmaceuticals, Inc. Stock Price stock today
news today CPRX – Catalyst Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch CPRX – Catalyst Pharmaceuticals, Inc. yahoo finance google finance
stock history CPRX – Catalyst Pharmaceuticals, Inc. invest stock market
stock prices CPRX premarket after hours
ticker CPRX fair value insiders trading